INTRODUCTION
In Europe, the reimbursement and funding process for biologic therapies is highly complex, with substantial differences between countries and further variations at regional and local levels in some countries. The process for a biologic obtaining a license in a second indication is even less clear
OBJECTIVE
We sought to gain a better understanding of the pricing and reimbursement processes, and evidence requirements at national, regional, and local levels with regard to a biologic obtaining a license in a second non-oncology indication in the United Kingdom (UK), France, Italy, and Spain
METHODS
In late 2013 and early 2014, we undertook a series of telephone interviews with payers and payer advisers (Table 1) . These discussions lasted one hour and followed an interview guide that had been developed in advance -In countries with a largely national system and no major local variations in terms of funding flow for biologics (UK [England] , and France), five telephone interviews were conducted -In countries with large variations at local and regional levels (Italy, and Spain), a greater number of interviews were conducted to capture these variations (18 and 17 interviews, respectively) 
RESULTS

RESULTS: UK (England)
In the UK (England), the pricing and reimbursement process is agreed at a national level, with few restrictions at regional and local levels. National Health Service (NHS) England is likely to be responsible for funding of new biologics and relies on guidance from the National Institute for Health and Care Excellence (NICE) before adopting a product in a new indication; therefore, demonstrating cost-effectiveness is key
Reimbursement and Funding Flow for Biologics
Reimbursement is agreed at a national level, following the recommendation issued by NICE Biologics are likely to be commissioned by NHS England, in agreement with NICE's recommendation ( 
Market Access Considerations
Demonstrating cost-effectiveness is key to securing a positive recommendation from NICE Strategic consideration of Patient Access Schemes may be helpful in demonstrating acceptable cost-effectiveness
Considerations for a Second Indication
The process is the same as that for a new drug (primary indication)
RESULTS: France
In France, the pricing and reimbursement process is agreed at a national level, with few restrictions at regional and local levels. Funding usually is through the groupe homogéne de séjour (GHS)
Reimbursement and Funding Flow for Biologics
Reimbursement is agreed at a national level following the assessment by the Transparency Commission (TC) Funding depends on the intended usage or dispensing: drugs are reimbursed within the cost of an average hospital stay or by health insurance, as long as the drug is used within the Marketing Authorisation Application (Figure 2) Usage/dispensing Used during hospital stay Classed within GHS (diagnosis-realated group system in France)
Reimbursed within the cost of an average hospital stay, according to national tariff
Dispensed from retail pharmacy
Reimbursed by health insurance (nurse time for administration and monitoring costs also reimbursed) 
Market Access Considerations
The amélioration du service médical rendu (ASMR) issued by the TC is important in achieving a high national price. The ASMR ranges from 1 to 5, where 1 corresponds to an innovative product of significant therapeutic benefit (for which a high price is possible) and 5 corresponds to no improvement (leading to a low price). This system is currently changing, however, and the service médical rendu (SMR)/ASMR system will be combined Pharmacoeconomic studies such as cost-effectiveness models may be required for high-cost drugs
Considerations for a Second Indication
RESULTS: Italy
In Italy, the Italian Medicines Agency (Agenzia Italiana del Farmaco [AIFA]) must approve a new biologic on a national level, with further pricing and reimbursement decisions on regional and local levels. Evidence requirements vary at each level (national, regional, and local)
Reimbursement and Funding Flow for Biologics
Reimbursement is agreed at national, regional, and local levels (with variation by region and sometimes by specific hospital) (Figure 3) Formulary decisions may be influenced by decisions taken in other regions or areas Regionally, biologics are funded according to their classification: Class A includes essential products and those for chronic diseases, these are fully reimbursed by the NHS; class H drugs are fully reimbursed in the hospital setting only
In some regions (including Campania, Friuli, Lombardy, Sicily, and Veneto), biologics are funded through special funding "File F" National Regional 1
Local
• AIFA approves pharmaceuticals and sets a national price
• Drugs are generally procured on a regional basis • Generally, if a product is approved by AIFA, inclusion on formularies should not be an issue
• In some regions (e.g., Emilia-Romagna, Tuscany), a local formulary also applies, in some cases the "Area Vasta" • In the majority of areas, hospital formularies are the final hurdle and a product must be included if market access is to be secured -However, in practice some regions (e.g., Veneto, Tuscany, Emilia-Romagna) are more demanding in terms of evidence requirements than other regions and can slow the process significantly, resulting in delays in access to a new product -The regions may restrict use to certain subpopulations 
Market Access Considerations
Regional formularies generally focus on efficacy and safety data, whereas local and hospital formularies require local epidemiology and budget-impact data If a product is considered an innovative medicine, patient access must be guaranteed across all regions
Considerations for a Second Indication
RESULTS: Spain
In Spain, once a drug is approved nationally by the Spanish Agency of Medicine (Agencia Española de Productos Sanitarios [AEMPS]), regions develop their own recommendations, and local decisions are made by hospital formularies. Evidence requirements vary at each level (national, regional, and local)
Reimbursement and Funding Flow for Biologics
• The pricing and reimbursement process is agreed at national, regional, and local levels (Figure 4) . Drugs are then procured at a regional level and restricted by hospital formularies • Once national and regional approval is achieved, in order for a drug to be listed on the formulary, clinicians must submit a report to the hospital pharmacy committee to ensure the product is available locally a In Valencia and Madrid, there is a patient copayment scheme for some patients or treatments (40%-60% of drug price); in other regions, the costs of drugs are fully reimbursed, but a copayment of approximately Ä5 for high-cost therapies is expected to be introduced in the near future. Aragon, Basque Country, Galicia, Madrid, and Valencia have a strong regional influence over local hospitals. 
Market Access Considerations
Data on efficacy and safety, comparative analysis with direct comparators, budget impact, cost-effectiveness, and epidemiology data are key at regional and local levels Performance metrics are important for expensive treatments (patients are closely monitored every 3 months)
Considerations for a Second Indication
No changes are expected compared to a process for a new drug (primary indication), but the price in the second indication is expected to be reduced
CONCLUSIONS
A biologic obtaining a license in a new indication must undergo the same process as a new product
The processes and restrictions for biologics may be stricter than for other medications because of their perceived high cost
The level of national, regional, and local requirements and restrictions varies; it is important that appropriate evidence is submitted to decision makers at each level 
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